NEW YORK ( TheStreet) -- Depomed (Nasdaq: DEPO) hit a new 52-week low Tuesday as it is currently trading at $4.35, below its previous 52-week low of $4.45 with 193,829 shares traded as of 10:04 a.m. ET. Average volume has been 912,800 shares over the past 30 days.

Depomed has a market cap of $273.5 million and is part of the health care sector and drugs industry. Shares are down 28.9% year to date as of the close of trading on Monday.

Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. The company has a P/E ratio of 2.9, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7.
  • Practice your DEPO trading strategies and win cash in our stock game.

TheStreet Ratings rates Depomed as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. You can view the full Depomed Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Young Guns of Activism Join Boards at AIG, SunOpta and DepoMed

Depomed Focuses on Flagship Drug Rather Than M&A: CEO